title: Withdrawal and psychological sequelae, and patient satisfaction associated with subcutaneous flumazenil infusion for the management of benzodiazepine withdrawal: a case series.
abstract: Our group and others internationally have previously reported data on the use of low-dose flumazenil administered intravenously for the management of benzodiazepine withdrawal. This paper describes the first reported use of subcutaneous flumazenil infusion in the management of acute benzodiazepine withdrawal. Self-reported withdrawal symptoms and psychological state and anxiety sequelae were collected at baseline and then at intervals to 5 days following initiation of subcutaneous flumazenil infusion. Data indicate that patient subjective benzodiazepine withdrawal symptoms were well managed, with significant reduction in psychological distress seen over the duration of treatment. Perceived difficulty in performing everyday functions was positively correlated with withdrawal severity and improved over treatment. Patients reported high treatment comfort, willingness to undertake a future subsequent treatment using this technique, and willingness to recommend this treatment to a friend. This small proof-of-concept study indicates that subcutaneous flumazenil infusion has excellent tolerability, efficacy and improvement on measures of psychological distress. Given this technique is less invasive and requires fewer staff resources compared with intravenous administration, it may prove a significant asset in the management of benzodiazepine withdrawal.
authors.affiliation: School of Psychiatry and Clinical Neurosciences, The University of Western Australia, Perth, Australia. gary.hulse@uwa.edu.au
authors.forename: Gary
authors.initials: G
authors.lastname: Hulse
authors.forename: George
authors.initials: G
authors.lastname: O'Neil
authors.forename: Noella
authors.initials: N
authors.lastname: Morris
authors.forename: Kellie
authors.initials: K
authors.lastname: Bennett
authors.forename: Amanda
authors.initials: A
authors.lastname: Norman
authors.forename: Sean
authors.initials: S
authors.lastname: Hood
mesh_terms: D000328:Adult; D000368:Aged; D001008:Anxiety Disorders / Q000209:etiology / Q000523:psychology; D001569:Benzodiazepines / Q000009:adverse effects*; D005260:Female; D005442:Flumazenil / Q000627:therapeutic use*; D006801:Humans; D055104:Infusions, Subcutaneous; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy* / Q000523:psychology*
chemical_list: D001569:Benzodiazepines; D005442:Flumazenil